文献速递前列腺增生与排尿功能障碍男科与性医学

可调节经闭孔男性吊带系统植入后的中期与长期结果

Intermediate- and Long-term Results After Adjustable Transobturator Male System Implantation.
PubMed 文献 · Urology · 2024-12-01

回顾性分析80例2010至2021年接受可调节经闭孔男性吊带系统(ATOMS)植入的男性压力性尿失禁患者,中位随访3年,每日尿垫数从4-2片显著减少(P<.001),1年与5年植入物存活率分别为0.89(95%CI:0.80-0.95)和0.71(95%CI:0.56-0.81),中位2.3年时22例(27.5%)取出。

要点

  • ATOMS植入后每日尿垫数从4-2片显著减少(P<.001),中位随访3年。
  • 5年内17例取出,1年与5年植入物存活率分别为0.89和0.71。
  • 既往抗尿失禁手术史、ISUP≥4及术前日尿垫重量>250g者取出风险更高。

核心结论

  • ATOMS可显著减少尿垫使用,中期随访约每3例患者中1例发生装置取出。
  • 作者指出,复发性压力性尿失禁和重度压力性尿失禁患者须被警告存在相关取出风险。

研究设计与样本

  • 回顾性分析2010至2021年在一家三级学术转诊中心接受ATOMS植入的80例男性压力性尿失禁患者数据。
  • 主要终点为控尿结局和并发症,采用Kaplan-Meier法估计植入物存活率,采用单变量Cox回归分析取出危险因素。

主要发现

  • 中位随访3年,每日尿垫数从4-2片显著减少(P<.001)。
  • 5年后17例经历取出,其中8例发生在ATOMS植入后第一年内,1年与5年植入物存活率分别为0.89(95%CI:0.80-0.95)和0.71(95%CI:0.56-0.81)。
  • 总观察期间,22例(27.5%)取出ATOMS(Kaplan-Meier取出估计值0.35[95%CI:0.09-0.64]),中位取出时间2.3(0.1, 10.2)年。
  • 既往抗尿失禁手术史者取出风险更高(HR=3.4,95%CI:1.4-8.2,P=.007)。
  • 手术标本ISUP≥4(Gleason评分≥8)者较ISUP 1者取出风险更高(HR=4.4,95%CI:1.03-27.1,P=.046)。

临床怎么用

  • 作者指出,复发性压力性尿失禁和重度压力性尿失禁患者须被警告存在相关取出风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess outcomes of continence and complications after implantation of Adjustable TransObturator Male System (ATOMS) for the treatment of male stress urinary incontinence (SUI). MATERIALS AND METHODS: Data of 80 patients receiving an ATOMS implantation between 2010 and 2021 at a tertiary academic referral center were retrospectively analyzed. Primary endpoints were outcomes of continence and complications. Implant survival rate was estimated by the Kaplan-Meier method, risk factors for explantation were analyzed by univariable Cox regression. RESULTS: During a median follow-up of 3 years, the number of pads decreased significantly from 4-2 pads per day (P<.001). After 5 years, 17 patients experienced an explantation, 8 of them during the first year following ATOMS implantation, resulting in 1- and 5-year-implant-survival rates of 0.89 (95%CI:0.80-0.95) and 0.71 (95%CI:0.56-0.81), respectively. During the total observation time, ATOMS was explanted in 22 (27.5%) patients (Kaplan-Meier estimate for explantation: 0.35 [95%CI:0.09-0.64]) after a median time of 2.3 (0.1, 10.2) years. The risk for explantation was higher in patients after previous incontinence surgery (HR=3.4, 95%CI:1.4-8.2, P=.007), ISUP (International Society of Urological Pathology) ≥4 (Gleason score ≥8) in surgery specimens (HR=4.4, 95%CI:1.03-27.1 compared to ISUP 1, P=.046), and a preoperative daily pad weight >250 g (HR=3.1, 95%CI:1.18-8.17, P=.022). CONCLUSION: ATOMS lead to a significant reduction of pad usage. During the intermediate-term follow-up, approximately every third patient experienced device explantation. In particular, patients with recurrent SUI and patients with severe SUI have to be warned about a relevant risk of explantation.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Jasarevic S, Jankovic D, Hutterer GC, et al. Intermediate- and Long-term Results After Adjustable Transobturator Male System Implantation. Urology. 2024. PMID: 39626835. doi:10.1016/j.urology.2024.11.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。